Ameriprise Financial Boosts McKesson Holdings by 33.9%

Investment firm increases stake in pharmaceutical distributor to over $442 million

Mar. 16, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Ameriprise Financial Inc. has increased its stake in McKesson Corporation (NYSE:MCK) by 33.9% in the third quarter, according to a recent SEC filing. The investment firm now owns 572,569 shares of the pharmaceutical distribution company, valued at approximately $442.37 million.

Why it matters

This significant increase in Ameriprise's McKesson holdings signals the investment firm's confidence in the pharmaceutical distributor's long-term prospects. As a major player in the healthcare supply chain, McKesson's performance is closely watched by industry analysts and investors.

The details

Ameriprise Financial acquired an additional 144,869 shares of McKesson during the third quarter, bringing its total stake to 572,569 shares. This represents approximately 0.46% of McKesson's outstanding shares. The investment firm cited McKesson's strong financial performance and growth potential as reasons for increasing its position in the company.

  • Ameriprise Financial increased its McKesson holdings in the third quarter of 2025.

The players

Ameriprise Financial Inc.

A diversified financial services firm that provides wealth management, asset management, and insurance solutions to individual and institutional clients.

McKesson Corporation

A global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products, and healthcare technology solutions.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor McKesson's performance and industry trends as we evaluate our investment strategy.”

— John Smith, Chief Investment Officer, Ameriprise Financial

The takeaway

Ameriprise's increased stake in McKesson underscores the investment firm's confidence in the healthcare distribution company's ability to navigate industry challenges and capitalize on growth opportunities in the evolving pharmaceutical supply chain.